Prot#13-0103: A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination with Ursodeoxycholic Acid (UDCA) Administered for 28 D

Project: Research project

Project Details

StatusFinished
Effective start/end date4/1/144/1/17

Funding

  • NGM Biopharmaceuticals, Inc. (Prot#13-0103)